LMN-201 Study: This study is testing a new drug, LMN-201, to see if it can help prevent the return of a stomach infection called C. difficile. People in the study will be taking antibiotics, which are medicines that fight bacteria, for this infection. The study is happening in multiple places to check if LMN-201 is safe and works well.

Key Points:

• Participants must be 18 or older and recently diagnosed with C. difficile.
• The study lasts up to 28 days, and you must be able to take oral medicine.
• Participants may not have other severe stomach issues and need a smartphone for the study.

To join, you should not have severe stomach problems like colitis, which is inflammation in the colon, or be in an intensive care unit. You also shouldn't have been treated with certain other medicines recently. Pregnant or breastfeeding individuals cannot participate. If you meet the criteria and agree, you'll be monitored to see how LMN-201 works for you. This study helps researchers see if LMN-201 can keep people from getting sick again with C. difficile.